IMV Reports the First Patient Dosing in the P-IIb (VITALIZE) Study for MVP-S + Keytruda (pembrolizumab) for the Treatment of R/R DLBCL
Shots:
- The first patient has been dosed in the P-IIb (VITALIZE) trial to evaluate the clinical benefit of IMV’s MVP-S + Merck’s Keytruda with/out CPA in ~150 patients with r/r DLBCL who have received 2 prior lines of systemic therapy & ineligible or failed ASCT or CAR-T therapy. The results are expected in summer 2022
- The 1EPs is ORR and measured by the number of patients achieving the best response of PR & CR @2yr. treatment period while exploratory EPs include cell-mediated immune response, tumor immune cell infiltration, and biomarker analysis
- Additionally, the results from the (SPiReL) study showed that MVP-S + Keytruda induced DCR, grade 1 or 2 AEs & showed 75% ORR in PD-L1+ patients
Ref: IMV | Image: IMV
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com